Company profile
Rinri Therapeutics Limited
Rinri Therapeutics has been founded on research into regenerative cell therapy for hearing loss
Rinri Therapeutics has been founded on pioneering research into regenerative cell therapy led by Professor Marcelo Rivolta at the University of Sheffield.
Corporate ownership
Updated 06 Jun 2026 16:52
Company events
Reference milestones and recent Companies House filing stream events.
Confirmation statement due
Confirmation DueNext confirmation statement due date
Accounts due
Accounts DueNext accounts due date
Resolution
ResolutionRESOLUTIONS | Transaction WUVZTElCNDBhZGlxemtjeA | Paper/PDF filed
Published 08 Apr 2026 22:50
Capital Name Of Class Of Shares
CapitalSH08 | Transaction MzUxMjU3NjM4M2FkaXF6a2N4 | Paper/PDF filed
Published 08 Apr 2026 22:50
Memorandum Articles
IncorporationMA | Transaction MzUxMjU3NjM4MGFkaXF6a2N4 | Paper/PDF filed
Published 08 Apr 2026 22:48
Capital Allotment Shares
CapitalSH01 | Transaction MzUxMjU3Njk2NGFkaXF6a2N4
Published 27 Mar 2026 07:08
Confirmation statement filed
ConfirmationLast confirmation statement made up date
Accounts filed
AccountsLast accounts made up date
Confirmation Statement With Updates
Confirmation-statementCS01 | Transaction MzQ0NDc4MTc0M2FkaXF6a2N4
Published 25 Nov 2024 02:17
Incorporated
InceptionCompany registered at Companies House
Spinout profile
Company description
Rinri Therapeutics develops therapeutics using stem cells to treat hearing disorders by replacing cells that are not working.
Although not a direct outcome of the this award, the spinout is related in the wider sense. Its purpose is to develop a treatment for hearing loss using human pluripotent stem cell derivatives
Project impact
Commercial In Confidence
Company has progressed developing its pipeline porfolio, atracting new funding from investors
Public funding
Projects
End-User Testing of a Novel Perfusion Bioreactor for Scalable Biomanufacturing of Cell Therapies
1 Aug 2025 to 30 Sep 2025
Allogeneic cell therapies - where a single donor-derived cell line is used to treat many patients - represent a transformative opportunity in modern medicine to address a wide range of conditions from cancer to neurological disorders. These therapies are often based on growing ('expanding') induced pluripotent stem cells (iPSCs) and then transforming ('di...
Preclinical development of a first in class stem cell therapy for hearing loss
1 Apr 2021 to 31 Mar 2023
Over 400m people have disabling hearing loss in the world, with this figure expected to nearly double by 2050\. Deafness has a devastating effect on people, significantly affecting quality of life, education and employment prospects. The direct and indirect costs of hearing loss are estimated at £30B a year for the UK alone due to direct costs of life lon...
Objective measurements of cochlear health using a cochlear implant: towards a biological therapy for hearing loss
1 Jan 2021 to 31 Oct 2025
The World Health Organisation reports deafness as the second leading cause of years lived with disability. Half a billion people in the world have disabling hearing loss resulting in enormous personal, social and economic hardship. The current standard of care for hearing loss are hearing devices, including hearing aids and cochlear implants. However, the...